title: Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans.
abstract: [(3R)-4-(4-Chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopentaindol-3-yl]acetic acid (MK-0524) is a potent orally active human prostaglandin D(2) receptor 1 antagonist that is currently under development for the prevention of niacin-induced flushing. The metabolism and excretion of [(14)C]MK-0524 in humans were investigated in six healthy human volunteers following a single p.o. dose of 40 mg (202 microCi). [(14)C]MK-0524 was absorbed rapidly, with plasma C(max) achieved 1 to 1.5 h postdose. The major route of excretion of radioactivity was via the feces, with 68% of the administered dose recovered in feces. Urinary excretion averaged 22% of the administered dose, for a total excretion recovery of approximately 90%. The majority of the dose was excreted within 96 h following dosing. Parent compound was the primary radioactive component circulating in plasma, comprising 42 to 72% of the total radioactivity in plasma for up to 12 h. The only other radioactive component detected in plasma was M2, the acyl glucuronic acid conjugate of the parent compound. The major radioactive component in urine was M2, representing 64% of the total radioactivity. Minor metabolites included hydroxylated epimers (M1/M4) and their glucuronic acid conjugates, which occurred in the urine as urea adducts, formed presumably during storage of samples. Fecal radioactivity profiles mainly comprised the parent compound, originating from unabsorbed parent and/or hydrolyzed glucuronic acid conjugate of the parent compound. Therefore, in humans, MK-0524 was eliminated primarily via metabolism to the acyl glucuronic acid conjugate, followed by excretion of the conjugate into bile and eventually into feces.
authors: Department of Drug Metabolism, Merck Research Laboratories, Rahway, NJ 07065, USA. bindhu_karanam@merck.com
authors: Bindhu
authors: B
authors: Karanam
authors: Maria
authors: M
authors: Madeira
authors: Scott
authors: S
authors: Bradley
authors: Larissa
authors: L
authors: Wenning
authors: Rajesh
authors: R
authors: Desai
authors: Eric
authors: E
authors: Soli
authors: David
authors: D
authors: Schenk
authors: Allen
authors: A
authors: Jones
authors: Brian
authors: B
authors: Dean
authors: George
authors: G
authors: Doss
authors: Graigory
authors: G
authors: Garrett
authors: Tami
authors: T
authors: Crumley
authors: Ajay
authors: A
authors: Nirula
authors: Eseng
authors: E
authors: Lai
mesh_terms: D000284:Administration, Oral; D001646:Bile / Q000378:metabolism; D001711:Biotransformation; D002250:Carbon Radioisotopes; D005243:Feces / Q000737:chemistry; D020719:Glucuronides / Q000378:metabolism; D006801:Humans; D006900:Hydroxylation; D007211:Indoles / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D007408:Intestinal Absorption; D008297:Male; D015394:Molecular Structure; D011971:Receptors, Immunologic / Q000037:antagonists & inhibitors*; D011982:Receptors, Prostaglandin / Q000037:antagonists & inhibitors*; D012016:Reference Values
chemical_list: D002250:Carbon Radioisotopes; D020719:Glucuronides; D007211:Indoles; C518174:MK-0524; D011971:Receptors, Immunologic; D011982:Receptors, Prostaglandin; C036293:prostaglandin D2 receptor